About

Dr. Jeffrey Chi has served on Aardvark's Board since May 2019 and as Lead Independent Director since December 2024. A veteran of the venture capital industry, he co-founded Vickers Venture Partners in 2005 and served as its Vice Chairman and a member of its Investment Committee until transitioning to a senior consultant role in 2025. He was Chairman and CEO of Vickers Vantage Corp. I from 2020 to 2022 and Chairman of the Singapore Venture Capital and Private Equity Association from 2013 to 2017. Dr. Chi received his Ph.D. and S.M. from the Massachusetts Institute of Technology and his M.A. and B.A. from the University of Cambridge, and is a CFA charterholder. He serves on Aardvark's Nominating and Corporate Governance, Compensation and Audit Committees.

Roles

Aardvark Therapeutics, Inc.
Lead Independent Director · Current role
May 2019–present
Vickers Venture Partners
Co-founder, Vice Chairman & Investment Committee member
2005 - 2025
Vickers Vantage Corp. I
Chairman & Chief Executive Officer
2020 - 2022
Singapore Venture Capital and Private Equity Association
Chairman
2013 - 2017
Pegasus Capital
Executive Director
Monitor Group
Senior Consultant
2001 - 2005

External Roles

Vivance Pte Ltd
Director
Jing-jin Electric Technologies Co., Ltd. (SH: 668280)
Director
MatchMove Pay Pte. Ltd.
Director

Director Compensation

FY 2025
Fees earned or paid in cash
$72,750
ComponentAnnual cash retainers and committee/leadership fees earned in 2025
Option awards
$536,120
ComponentStock options granted during 2025, ASC 718 grant-date fair value
Total
$608,870

Also at Aardvark Therapeutics, Inc.

Related

See how VectorShift works for your firm

Request Demo